Skip to main content
Equibles

RA CAPITAL MANAGEMENT, L.P.

Position in AKTS — Aktis Oncology, Inc.

CIK 1346824 BOSTON, MA
Back to AKTS Full portfolio

Position in AKTS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$42,363,273
+$15,473,101 QoQ
Shares Held
1,314,405
-12.6% QoQ
Ownership
2.36%
of shares outstanding
% of Portfolio
0.37%
of 13F equity value
Holder Rank
#8
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in AKTS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

RA CAPITAL MANAGEMENT, L.P. holds $11,082,969,028 across 75 Biotechnology names. AKTS ranks #42 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ASND
Ascendis Pharma A/S
 10,281,496 $2,742,280,613
2 PBLS
Parabilis Medicines, Inc.
 28,933,371 $791,906,364
3 RYTM
Rhythm Pharmaceuticals, Inc.
 6,666,837 $740,218,912
4 PCVX
Vaxcyte, Inc.
 11,474,599 $667,018,439
5 SION
Sionna Therapeutics, Inc.
 9,905,045 $435,722,929
6 TYRA
Tyra Biosciences, Inc.
 12,198,625 $389,624,082
7 EWTX
Edgewise Therapeutics, Inc.
 8,392,730 $340,996,619
8 NAMS
NewAmsterdam Pharma Co N.V.
 9,883,524 $330,779,298

All Filings in AKTS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $42,363,273 1,314,405
2026-03-31 $26,890,172 1,503,084